Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen non-GAAP Diluted Earnings Per Share ($/sh) ($)
Form 8-K Reconciliations of GAAP to Non-GAAP Measures
Latest, Q2 2026
6.29
Period ended Jun 30, 2026
Change on a year earlier
+4.5%
6.02 in Q2 2025
History
34 quarters
Since Q3 2017
Sources
30
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up non-gaap diluted earnings per share ($/sh)
Cite this data
StockData. (2026). Amgen Non-GAAP Diluted Earnings Per Share ($/sh) ($), quarterly Q3 2017–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/ng_eps_diluted
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.